# Efficacy and Safety Study of ABT-384 in Subjects With Mild-to-Moderate Alzheimer's Disease

> **NCT01137526** · PHASE2 · COMPLETED · sponsor: **AbbVie (prior sponsor, Abbott)** · enrollment: 267 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** ABT-384
- **DRUG:** donepezil
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT01137526
- **Lead sponsor:** AbbVie (prior sponsor, Abbott)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-05
- **Primary completion:** 2011-07
- **Final completion:** 2011-07
- **Target enrollment:** 267 (ACTUAL)
- **Last updated:** 2013-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01137526

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01137526, "Efficacy and Safety Study of ABT-384 in Subjects With Mild-to-Moderate Alzheimer's Disease". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01137526. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*